Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Bioxytran ( (BIXT) ) has provided an announcement.
Bioxytran, Inc., a clinical-stage biotechnology company developing therapies for hypoxia-related conditions and galectin-targeting technologies across viral, metabolic, and inflammatory diseases, is also moving into select commercial applications based on its proprietary platform. The company’s strategy combines pharmaceutical R&D with nearer-term commercial products to diversify its revenue potential and support long-term growth.
On March 18, 2026, Bioxytran completed a $1.2 million private placement, issuing about 21.1 million common shares at roughly $0.055 each and warrants for up to 19.75 million additional shares at $0.12, exercisable for five years. The financing, disclosed on March 20, 2026, strengthens the balance sheet, funds working capital and development programs, supports commercialization efforts including the planned launch of its A-SUQAR dietary supplement this quarter, and creates potential for further capital inflows if warrants are exercised.
More about Bioxytran
Bioxytran, Inc. is a clinical-stage biotechnology company focused on developing therapeutics targeting hypoxia-related conditions and galectin-targeting carbohydrate technologies, with applications in infectious viral diseases, metabolic health, and inflammation. The company pursues both pharmaceutical development programs and select commercial applications, leveraging its proprietary platform to address significant unmet medical needs.
Average Trading Volume: 368,057
Technical Sentiment Signal: Sell
Current Market Cap: $3.58M
Learn more about BIXT stock on TipRanks’ Stock Analysis page.